Sanofi (NASDAQ:SNY) Shares Gap Up – Time to Buy?

Sanofi (NASDAQ:SNY) shares gapped up before the market opened on Tuesday . The stock had previously closed at $45.89, but opened at $47.65. Sanofi shares last traded at $47.85, with a volume of 453,757 shares trading hands.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Sanofi currently has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Stock Performance

The stock has a market capitalization of $119.30 billion, a P/E ratio of 23.98, a P/E/G ratio of 1.23 and a beta of 0.58. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The business’s fifty day moving average price is $50.56 and its two-hundred day moving average price is $52.05.

Sanofi (NASDAQ:SNY) last announced its earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. During the same quarter in the previous year, the business earned $2.55 EPS. The company’s quarterly revenue was up 12.3% on a year-over-year basis. As a group, sell-side analysts forecast that Sanofi will post 4.06 earnings per share for the current year.

Hedge Funds Weigh In On Sanofi

Several hedge funds have recently added to or reduced their stakes in SNY. Stablepoint Partners LLC lifted its stake in shares of Sanofi by 0.8% during the 3rd quarter. Stablepoint Partners LLC now owns 23,893 shares of the company’s stock worth $1,377,000 after acquiring an additional 189 shares during the last quarter. PDS Planning Inc grew its stake in Sanofi by 3.1% in the third quarter. PDS Planning Inc now owns 6,643 shares of the company’s stock worth $383,000 after purchasing an additional 200 shares in the last quarter. Eagle Ridge Investment Management increased its holdings in Sanofi by 3.8% during the 3rd quarter. Eagle Ridge Investment Management now owns 5,571 shares of the company’s stock worth $321,000 after purchasing an additional 203 shares during the period. Financial Advocates Investment Management lifted its holdings in shares of Sanofi by 3.4% in the 3rd quarter. Financial Advocates Investment Management now owns 6,327 shares of the company’s stock worth $365,000 after buying an additional 206 shares during the period. Finally, Angeles Investment Advisors LLC raised its holdings in shares of Sanofi by 1.9% in the third quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company’s stock valued at $653,000 after acquiring an additional 210 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.